Drugs / TYRA-430
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06915753 | Apr 2025 → Jan 2028 expected | hepatocellular carcinoma | Tyra Biosciences, Inc | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TYRA-430 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06915753 ↗ |
| Action | Inhibit | “a first-in-class, selective, reversible fibroblast growth factor receptor (FGFR) 4 and 3 inhibitor” NCT06915753 ↗ |
| Route | Oral | “Oral TYRA-430 given daily.” NCT06915753 ↗ |